MedTrace Logo

BUSCLAB - Buscopan to Prevent Slow Progress in Labor

NCT03961165 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2022-12-20

No results posted yet for this study

Summary

To study the effect of Butylscopolamine Bromide on duration of the active phase of first stage of labor in first time mothers who cross the alert-line for labor dystocia, according to the WHO partograph.

Conditions

  • Labor (Obstetrics)--Complications
  • Labor; Prolonged, First Stage

Interventions

DRUG

Butylscopolamine Bromide 20 MG/ML

1 mL Butylscopolamine Bromide 20 mg/mL i.v. Single dose.

DRUG

Sodium Chloride 9mg/mL

1 mL Sodium Chloride 9 mg/mL i.v. Single dose.

Sponsors & Collaborators

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Trond M Michelsen, MD, PhD · Oslo University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-25
Primary Completion
2021-08-29
Completion
2022-06-16

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03961165 on ClinicalTrials.gov